Janssen Pharmaceuticals Inc.

09/19/2021 | Press release | Distributed by Public on 09/19/2021 13:09

RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small[...]